https://www.selleckchem.com/pr....oducts/Dihydroartemi
Furthermore, mice administered sub-maximal doses of the GC activator cinaciguat together with the PDE inhibitor dipyridamole and prasugrel, showed significant inhibition of ex vivo platelet aggregation and significantly reduced in vivo arterial thrombosis in response to injury without alteration in basal carotid artery blood flow. CONCLUSIONS Using in vitro, ex vivo and in vivo functional studies, we show that low dose GC activators synergise with P2Y12 inhibition to produce powerful anti-platelet effects without alterin
Like
Comment
Share
